Centre Bans High‑Dose Nimesulide Painkiller: What Patients Need to Know Now

The Union Health Ministry has banned the manufacture, sale and distribution of all oral formulations of the widely used painkiller nimesulide above 100 mg in immediate‑release form across India, citing human health risks and the availability of safer alternatives. The move, notified on 29 December under the Drugs and Cosmetics Act, takes effect immediately and is expected to significantly reshape how pain and fever are managed in clinics and pharmacies nationwide.​

What has the government banned?

The notification bars any oral immediate‑release nimesulide product containing more than 100 mg from being manufactured, stocked, sold or distributed in India. Lower‑dose formulations up to 100 mg remain outside the scope of this order, although they are already subject to age‑based restrictions and prescribing cautions.​

• The order has been issued under Section 26A of the Drugs and Cosmetics Act, 1940, which empowers the central government to regulate, restrict or prohibit a drug in the public interest.​

• The ban follows recommendations of the Drugs Technical Advisory Board (DTAB) and safety reviews commissioned from the Indian Council of Medical Research (ICMR).​

• Popular brands in India include Nise, Nimulid, Nicip and Nimtech, many of which have been sold in strengths at or above 100 mg for pain and fever relief.​

The Health Ministry has stated it is “satisfied” that continued use of higher‑dose nimesulide is likely to involve risk to human beings and that prohibiting such formulations is necessary in the public interest.​

Why is nimesulide under scrutiny?

Nimesulide is a non‑steroidal anti‑inflammatory drug (NSAID) with relative COX‑2 selectivity, used to treat acute pain, inflammation and fever. It has long been controversial because of its potential to cause liver injury, leading to suspensions or withdrawals in several countries and repeated safety reviews in India.​

• A 2019 systematic review and meta‑analysis of 25 observational studies found that nimesulide use was associated with about a twofold increase in the risk of hepatotoxicity (relative risk 2.21, 95% confidence interval 1.72–2.83) compared with no exposure or other NSAIDs.​

• In pharmacovigilance database analyses, nimesulide users had a nearly fourfold higher reporting odds ratio for liver‑related adverse events compared with users of other NSAIDs.​

• Case reports and series have described fulminant hepatic failure, liver transplantation and deaths, sometimes after less than 15 days of therapy.​

LiverTox, a U.S. National Institutes of Health reference, notes that nimesulide has been “linked to many instances of clinically apparent acute liver injury that can be severe and can result in acute liver failure, need for emergency liver transplantation and death.” At the same time, some clinical studies in India have reported only modest changes in liver enzymes with short‑term nimesulide use at 100 mg twice daily, underscoring that severe toxicity, while uncommon, can be unpredictable and serious when it occurs.​

Regulatory history and expert concerns

India’s drug regulators have been tightening controls on nimesulide for more than a decade. In 2011, the central government banned its use in children below 12 years after DTAB raised concerns about liver toxicity.​

More recently, the DTAB asked ICMR to undertake a detailed safety evaluation in adult patients. Based on that assessment, ICMR recommended:​

• A ban on all nimesulide preparations above 100 mg for adults.

• Restricting use in people younger than 18 years and older than 60 years.

• Strong warnings (including a “black box” style caution) to avoid use in pregnant or breastfeeding women and in people with liver or kidney disease.​

A senior internal‑medicine specialist from a large Delhi hospital, who was not involved in the government review, notes that the pattern mirrors global actions: “When a painkiller is repeatedly tied to severe liver damage, regulators start by restricting vulnerable groups and higher doses before deciding whether any continued use is justified,” the physician says, adding that the high‑dose ban is “a logical next step” in India’s risk‑reduction pathway.​

How big is the risk?

The absolute risk of serious liver injury with nimesulide remains relatively small, but higher than with many other commonly used NSAIDs. In an Italian cohort and nested case‑control study of around 400,000 residents, current NSAID use in general was associated with a 1.4‑fold increased risk of hepatopathy compared with past use, while nimesulide specifically showed a 1.9‑fold higher risk for more severe liver injury.​

Key points from the evidence base include:

• Meta‑analysis data show increased relative risk, but exact risk for an individual person depends on age, underlying liver health, dose and duration.​

• Women and older adults appear over‑represented among reported severe cases.​

• Many severe events occurred within the first two weeks of treatment, meaning that even short courses are not risk‑free.​

An independent hepatologist at a tertiary liver centre in South India explains: “Most patients will never experience serious problems, but we cannot accurately predict who will. When safer options exist, even a low absolute risk can become unacceptable—especially at higher doses.”​

What does this mean for patients and doctors?

For people living with pain or recurrent fever, the ban may raise immediate questions about what to take instead. Clinicians emphasise that several other NSAIDs and paracetamol‑based regimens remain available and can be chosen based on the person’s age, medical history and type of pain.​

Practical implications include:

• Existing prescriptions: Patients currently taking high‑dose immediate‑release nimesulide (above 100 mg) should not stop abruptly without talking to their doctor, but should seek prompt medical advice on switching to an alternative.​

• Pharmacy access: Retailers are now legally barred from dispensing the banned strengths and must return or dispose of remaining stock as per regulatory instructions.​

• Self‑medication: Nimesulide is a Schedule H drug, which means it should be sold only on prescription, yet reports suggest it has often been obtained over the counter in India. Experts say the ban on higher‑dose products should be coupled with stricter enforcement to curb unsafe self‑medication.​

For routine pain and fever, doctors typically rely on paracetamol, ibuprofen and other NSAIDs with longer safety experience, adjusting dose and duration carefully. However, each alternative also carries its own risks, from kidney effects to stomach bleeding, especially in older adults or those with chronic conditions, which is why personalised prescribing remains essential.​

Limitations, unanswered questions and ongoing debate

While the evidence linking nimesulide to liver injury is substantial, researchers and regulators acknowledge some limitations. Most data come from observational studies and adverse‑event reporting systems, which can be prone to reporting bias and confounding by underlying illness or co‑medications.​

Areas of ongoing debate include:

• Dose–response clarity: Although higher doses and longer use appear to increase risk, the exact relationship between dosage (for example, 100 mg vs 200 mg) and liver injury is not fully defined.​

• Comparisons with other NSAIDs: Some studies suggest that the absolute risk with nimesulide is still low and overlaps with that of other NSAIDs, leading some clinicians to argue for tighter monitoring rather than outright bans.​

• Role of genetic and metabolic factors: Researchers continue to explore why only a small subset of users develop severe toxicity, including possible genetic susceptibility or interactions with alcohol and other medications.​

Despite these uncertainties, many regulators in Europe and elsewhere have limited nimesulide use or removed it from the market, particularly for long‑term treatment, on the precautionary principle. India’s new high‑dose ban fits within that global pattern of tightening controls while leaving some restricted use in lower doses.​

How can the public use painkillers more safely?

Experts stress that the nimesulide decision should prompt broader reflection on how all painkillers are used, rather than causing panic about one medicine. Simple precautionary steps can reduce the risk of drug‑related harm:​

• Take painkillers only on medical advice, especially if you have liver, kidney, heart or stomach problems or take multiple medications.​

• Avoid combining multiple over‑the‑counter pain medicines without checking with a doctor or pharmacist, as this can duplicate doses or increase toxicity.​

• Limit duration to the shortest possible period; if pain or fever persists beyond a few days, seek medical evaluation instead of repeatedly self‑medicating.​

• Watch for early warning signs of liver trouble while on any medication—such as unusual fatigue, nausea, dark urine, yellowing of the eyes or skin—and seek urgent care if these appear.​

As one internal‑medicine consultant notes, “No painkiller is completely risk‑free, but rational prescribing, patient education and vigilant monitoring can keep those risks low. The high‑dose nimesulide ban is a reminder that safety signals must be acted on early, not after harm is widespread.”​

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health‑related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References

Regulatory and policy documents

• Ministry of Health and Family Welfare, Government of India. Gazette notification banning oral formulations of nimesulide above 100 mg in immediate‑release form; 29 Dec 2025.pharmabiz+1​